Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
Andrews, F.H., Singh, A.R., Joshi, S., Smith, C.A., Morales, G.A., Garlich, J.R., Durden, D.L., Kutateladze, T.G.(2017) Proc Natl Acad Sci U S A 114: E1072-E1080
- PubMed: 28137841 
- DOI: 10.1073/pnas.1613091114
- Primary Citation of Related Structures:  
5U28, 5U2C, 5U2E, 5U2F - PubMed Abstract: 
MYC is a major cancer driver but is documented to be a difficult therapeutic target itself. Here, we report on the biological activity, the structural basis, and therapeutic effects of the family of multitargeted compounds that simultaneously disrupt functions of two critical MYC-mediating factors through inhibiting the acetyllysine binding of BRD4 and the kinase activity of PI3K ...